Microbot Medical Inc.
Microbot Medical Inc. (MBOT) Stock Overview
Explore Microbot Medical Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
95.7M
P/E Ratio
-4.91
EPS (TTM)
$-0.64
ROE
-0.85%
MBOT Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Microbot Medical Inc. (MBOT) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 56.77, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $0.67.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -4.91 and a market capitalization of 95.7M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Technical Indicators
Analyst Recommendations
Price Targets
Company Profile
Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company, through its ViRob, TipCAT, CardioSert, and Liberty micro-robotic technologies, developing Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; a disposable robot for various endovascular interventional procedures; and a multi generation pipeline portfolio. It has 42 issued/allowed patents and 23 patent applications pending worldwide. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Hingham, Massachusetts.
Harel Gadot
20
25 Recreation Park Drive, Hingham, MA
1992